These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1177 related articles for article (PubMed ID: 3138195)

  • 1. Interferon-gamma-induced alterations of monocyte susceptibility to lysis by autologous lymphokine-activated killer (LAK) cells.
    Djeu JY; Blanchard DK
    Int J Cancer; 1988 Sep; 42(3):449-54. PubMed ID: 3138195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
    Blanchard DK; Djeu JY
    J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of human monocyte susceptibility to lymphokine-activated killer cell lysis by granulocyte-macrophage colony-stimulating factor.
    Blanchard DK; Serbousek D; Djeu JY
    Cancer Res; 1989 Sep; 49(18):5037-43. PubMed ID: 2670200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of monocytes to lymphokine-activated killer cell lysis: effect of granulocyte-macrophage colony-stimulating factor and interleukin-3.
    Djeu JY; Widen R; Blanchard DK
    Blood; 1989 Apr; 73(5):1264-71. PubMed ID: 2649172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
    de Fries RU; Golub SH
    J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes.
    Singh SM; Sone S; Inamura N; Ogura T
    Int J Cancer; 1989 Jul; 44(1):170-6. PubMed ID: 2663733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon is able to reduce tumor cell susceptibility to human lymphokine-activated killer (LAK) cells.
    Grönberg A; Ferm M; Tsai L; Kiessling R
    Cell Immunol; 1989 Jan; 118(1):10-21. PubMed ID: 2463094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF-alpha and IFN-gamma reverse IL-4 inhibition of lymphokine-activated killer cell function.
    Swisher SG; Economou JS; Holmes EC; Golub SH
    Cell Immunol; 1990 Jul; 128(2):450-61. PubMed ID: 2113430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of human monocyte function against Candida albicans by autologous IL-2-induced lymphokine-activated killer cells.
    Wei S; Serbousek D; McMillen S; Blanchard DK; Djeu JY
    J Immunol; 1991 Jan; 146(1):337-42. PubMed ID: 1898605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of interferon gamma-induced protection of human gliosarcoma cells from lymphokine-activated killer lysis: division of lymphokine-activated killer cells into natural killer- and T-like cells.
    Kondo S; Miyatake S; Kikuchi H; Oda Y; Iwasaki K; Ohyama K; Namba Y
    Neurosurgery; 1992 Sep; 31(3):534-40. PubMed ID: 1407434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
    Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
    Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
    Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
    Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphokine-activated killer cell regulation of T-cell-mediated immunity to Candida albicans.
    Wei S; Blanchard DK; McMillen S; Djeu JY
    Infect Immun; 1992 Sep; 60(9):3586-95. PubMed ID: 1500166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-gamma reduces the sensitivity of cultured and fresh human tumor cells to lysis by lymphokine-activated killer cells.
    de Fries RU; Golub SH
    Nat Immun Cell Growth Regul; 1988; 7(2):65-76. PubMed ID: 3137461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
    J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Killing of alveolar macrophages and of monocytes that have responded to granulocyte-macrophage colony-stimulating factor by human lymphokine-activated killer cells.
    Sone S; Inamura N; Singh SM; Okubo A; Yanagawa H; Nakanishi M; Ogura T
    Jpn J Cancer Res; 1989 Jul; 80(7):662-9. PubMed ID: 2507489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential modulation of surface antigens on human macrophages by IFN-gamma and GM-CSF: effect on susceptibility to LAK lysis.
    Blanchard DK; Djeu JY
    J Leukoc Biol; 1991 Jul; 50(1):28-34. PubMed ID: 1905335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up- and down-regulation of human lymphokine (IL-2)-activated killer cell induction by monocytes, depending on their functional state.
    Nii A; Sone S; Utsugi T; Yanagawa H; Ogura T
    Int J Cancer; 1988 Jan; 41(1):33-40. PubMed ID: 2826345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphokine-activated killer (LAK) cells: interferon-gamma synergizes with interleukin-2 to induce LAK cytotoxicity in homogeneous leukemic preparations.
    Kaufmann Y; Davidsohn J; Levanon M; Icekson I; Revel M; Ramot B
    Clin Immunol Immunopathol; 1991 Feb; 58(2):278-88. PubMed ID: 1898716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.